Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

ALDX 11.14.2024

Full Press ReleaseSEC FilingsOur ALDX Tweets

About Gravity Analytica

Recent News

  • 12.05.2024 - Citi 2024 Global Healthcare Conference
  • 12.02.2024 - Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
  • 11.21.2024 - Jefferies London Healthcare Conference

Recent Filings

  • 11.18.2024 - EX-99.1 EX-99.1
  • 11.18.2024 - 8-K Current report
  • 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
PDF Version

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 14, 2024--Aldeyra Therapeutics, Inc.(Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced thatTodd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at theJefferies London Healthcare Conference2024. The conference is being conducted inLondon, EnglandNovember 19- 21, 2024.

Dr. Brady’s conversation withKelly Shi, Ph.D., Senior Vice President,Biotechnology Equity ResearchatJefferies LLC., is scheduled to begin at12:30 p.m. GMT Thursday, November 21, 2024. To view the live webcast, log in to the Investors & Media section of the Aldeyra website athttps://ir.aldeyra.com. Following the fireside chat, the webcast will be archived for 90 days.

About Aldeyra

Aldeyra Therapeuticsis a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241114786147/en/

Investor & Media Contact:Laura NicholsTel: (781) 257-3060investorrelations@aldeyra.com

Source:Aldeyra Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com